Product Information
PALIPERIDONE ER 3 MG TABLET is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.9719 per EA under NDC 43975035003. Its NADAC has been published 335 times since May 6, 2020.
FDA first approved this application on Jun 12, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
43975035003
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PALIPERIDONEApproval Type
Generic (ANDA)
FDA Application
ANDA204452FDA Approved
6/12/2019
TE Code
AB
On Market Since
11/27/2019
Pharmacological Classes
Price Statistics
The NADAC for PALIPERIDONE ER 3 MG TABLET has been published 335 times since May 6, 2020, and over the history we have for it it has declined 88.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9719 per EA |
|---|---|
| All-time high | $9.3768 (Jun 10, 2020) |
| All-time low | $0.9120 (Aug 19, 2026) |
| 52-week high | $1.2652 |
| 52-week low | $0.9120 |
| Median price | $1.9114 |
| Average price | $3.4268 |
| Largest weekly change | +62.1% (Jul 21, 2021) |
| Weeks tracked | 335 |
| Tracking since | May 6, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the PALIPERIDONE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PALIPERIDONE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PALIPERIDONE ER 3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PALIPERIDONE ER 3 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $0.9719 per EA (NDC 43975035003), effective Sep 30, 2026.
How has the price of PALIPERIDONE ER 3 MG TABLET changed over time?
Over the history we have for it, the NADAC for PALIPERIDONE ER 3 MG TABLET has declined 88.3%. It has been tracked across 335 weekly CMS publications since May 6, 2020.
What are the highest and lowest recorded NADAC prices for PALIPERIDONE ER 3 MG TABLET?
Since May 6, 2020, the NADAC for PALIPERIDONE ER 3 MG TABLET has ranged from a low of $0.9120 (Aug 19, 2026) to a high of $9.3768 (Jun 10, 2020), with a median of $1.9114 per EA.
Are there cheaper alternatives to PALIPERIDONE ER 3 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PALIPERIDONE ER 3 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PALIPERIDONE ER 3 MG TABLET?
PALIPERIDONE ER 3 MG TABLET (NDC 43975035003) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.